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Cell therapies are currently used to treat many haematological diseases. These treatments 
range from the long-term reconstitution of the entire haematopoietic system using the 
most potent haematopoietic stem cell (HSC) to the short-term rescue with mature 
functional end cells such as oxygen-carrying red blood cells and cells of the immune system 
that can fight infection and repair tissue. Limitations in supply and the risk of transmitting 
infection has prompted the design of protocols to produce some of these cell types from 
human pluripotent stem cells (hPSCs). Although it has proven challenging to generate the 
most potent HSCs directly from hPSCs, significant progress has been made in the 
development of differentiation protocols that can successfully produce haematopoietic 
progenitor cells and most of the mature cell lineages. We review the key steps used in the 
production of haematopoietic stem and progenitor cells (HSPCs) from hPSCs and the cell 
surface markers and reporter strategies that have been used to define specific transitions. 
Most studies have largely relied on the use of known markers that define HSPC production 
in vivo but more recently single cell RNA sequencing has allowed a less biased approach to 
their characterisation. Transcriptional profiling has identified new markers for naïve and 
committed hPSC-derived HSPC populations and trajectory analyses has provided novel 
insights into their lineage potential. Direct comparison of in vitro- and in vivo-derived RNA 
single cell sequencing datasets has highlights similarities and differences between the two 
systems and this deeper understanding will be key to the design and the tracking of 
improved and more efficient differentiation protocols. 
 
1. Cell therapy for haematopoietic disorders and deficiencies 
 
Cell therapy has been used for decades to treat blood and immune cell disorders.  
Haematopoietic stem cells (HSC) derived from bone marrow, umbilical cord blood or 
mobilised peripheral blood can reconstitute the entire haematopoietic system in the long 
term and can be used to treat cancer patients when their haematopoietic system has been 
ablated by the toxic effects of chemotherapy (1). HSC transplantation also provides a life-
long cure for patients with specific genetic disorders that affect the production or function 
of cells of the blood or immune system. The rapid advances in genetic editing using CRISPR-
CAS9 strategies makes gene correction of patient-derived HSCs a realistic option in single 
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gene disorders including Wiskott-Aldrich syndrome, chronic granulomatous disease and 
severe combined immunodeficiency in the future (2-4). Current standard practise is to use 
HSCs derived from healthy donors but incomplete immunological matching can lead to 
graft-versus-host disease (5, 6).  
 
Red blood cell (RBC) loss following trauma or during surgery and genetic disorders including 
anaemias and thalassamias can be treated in the short term by the transfusion of donor-
derived RBCs (7). Platelet transfusion is used to prevent bleeding in people with clotting 
disorders or low platelet counts of cancer patients receiving chemotherapy (8).  More 
recently there is also increasing interest in the therapeutic application of other mature 
haematopoietic cells including T cells and natural killer cells as novel cancer treatments and 
macrophage lineage as a cell therapy for liver fibrosis (9-12).  
 
As stated above, these  therapeutic haematopoietic cells are primarily sourced from 
allogeneic donors but there are limitations in supply and, despite HLA matching of HSC 
transplants, there remains a requirement for immunosuppression to avoid rejection and 
graft-versus-host disease (6).  Some b-thalassaemia patients require life-long regular blood 
transfusions that can result in complications including haemolytic transfusion reactions, 
transfusion-associated graft-versus-host disease and circulatory overload (7, 13). The 
potential to generate these cells from human pluripotent stem cells (hPSCs) could provide a 
limitless, off-the-shelf source of therapeutic cells that it more amenable to genetic editing 
compared to primary HSCs and the advent of induced pluripotent stem cell (iPSC) 
technology could offer an autologous resource (14, 15).  Most cells of the haematopoietic 
hierarchy can be generated in vitro from hPSCs but it has become clear that PSC-derived 
cells are not entirely equivalent to their in vivo counterparts (15, 16)(Table 1).  For example, 
it has not been possible to generate long-term reconstituting HSCs in vitro without 
significant genetic intervention and the final enucleation step in the production of fully 
mature red blood cells does not occur efficiently (17, 18). T lineage cells can be generated 
but positive selection and the production of mature T cells from human PSCs have been 
limited (19).  The production of functional platelets from iPSC-derived megakaryocytes can 
be achieved but scaling up of this process to generate enough cells for therapy remains a 
significant challenge (20). Cells of the monocyte/macrophage lineage can be produced at 
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scale (21) but it is particularly interesting to note that these are considered to be more akin 
to myeloid cells generated in the embryo that go on to seed the resident populations  within 
specific tissues rather than adult bone marrow derived cells (22). This is in keeping with the 
widely accepted idea that PSC differentiation recapitulates embryonic, but not adult 
haematopoiesis. Functional deficiencies in PSC-derived cells are likely to reflect the 
progenitor cells from which they originate. Thus, it is critical to consider the strategy for 
production of haematopoietic stem and progenitor cells (HSPCs) in vitro, to fully 
characterise the HSPCs that can be produced and to compare these to their in vivo 
counterparts. Here we briefly review HSPC production in vivo and reflect on the lessons that 
have been learned and applied to in vitro differentiation protocols. We summarise the 
molecular markers that have been used to define the specific stages and transitions and 
conclude by describing more recent transcriptional profiling and machine learning that has 
uncovered novel insights into the process. 
 
2. Production of haematopoietic stem and progenitor cells in vivo 
 
The development of HSPCs during mammalian development is complex and the process is 
precisely coordinated both temporally and spatially (23, 24). First characterised in the 
mouse embryo, there is increasing evidence demonstrating that the spatial organisation and 
the chronological timing is comparable during human embryogenesis (25, 26). The first 
blood cells arise in the extraembryonic yolk sac and include primitive embryonic 
erythrocytes, megakaryocytes and macrophages (27). This is followed by the appearance of 
erythromyeloid progenitors (EMPs) from the same location that have the additional 
potential of production of granulocytes and NK cells (28, 29). The most potent 
haematopoietic stem cells (HSC) capable of long-term reconstitution first arise in the ventral 
wall of the dorsal aorta in the aorta-gonad-mesonephros (AGM) region (23, 30) that 
subsequently colonise and expand in the foetal liver (31).  HSCs then migrate to the bone 
marrow where the lifelong production of adult blood and immune cells is controlled within 
this specialised haematopoietic niche (32). 
   
3. Production of haematopoietic stem and progenitor cells from pluripotent stem 
cells in vitro. 
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It is widely accepted that the first two waves of haematopoiesis can be recapitulated in vitro 
from both mouse and human PSCs in vitro but it has proven more challenging to identify 
long-term reconstituting HSCs similar to those derived in the AGM (Table 1) (26, 33, 34). The 
fact that HSCs can be produced in the human iPSC-derived teratoma setting implies that 
hPSCs have the intrinsic potential to give rise to this cell type in the appropriate 
environment (35, 36). The capacity of the microenvironment to unlock the potential of 
hPSC-derived cells has also been implied by the multilineage long-term reconstitution of 
genetically modified hemogenic endothelium following injection into the bone marrow of 
recipient mice (37). There are several reports of other genetic programming strategies have 
resulted in the successful production of HSCs from hPSCs  (37, 38). However, although 
providing invaluable insights into the mechanisms associated with cell production, teratoma 
and genetic programming strategies would be really challenging to translate into the clinical 
setting. Thus, the ultimate goal in the field is to discover well defined and controllable 
culture conditions that result in the efficient production of fully functional haematopoietic 
cell types. 
 
Initial studies aiming to produce haematopoietic cells from hPSCs involved the use of serum-
containing media and co-culture with supportive stromal cell lines derived from the various 
haematopoietic tissue including bone marrow, foetal liver and AGM (14, 39, 40). Robust 
multi-lineage CFU-Cs were generated under such conditions but these first protocols have 
since been replaced with much more defined serum- and feeder-free protocols involving the 
stepwise addition of recombinant cytokines and small molecules to activate or inhibit 
specific signalling pathways (16, 41, 42). One of the first refinements of the differentiation 
protocols used the knowledge that the haematopoietic lineages are derived from the 
mesoderm germ layer and that the addition of BMP4 to differentiating mouse ESCs could 
initiate a process resembling primitive streak formation that proceeds mesoderm induction 
(41).  
 
3.1. Induction and patterning of mesoderm 
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Mesoderm forms during early embryogenesis  following the ingression of undifferentiated 
epiblast cells  through the primitive streak (PS) with distinct regions of the PS  inducing 
different subpopulations of mesoderm that then goes on to form distinct cell lineages 
including haematopoietic cells (43). Anterior-posterior positioning in the epiblast and the 
initiation of gastrulation is controlled by the complex interplay of WNT, Nodal and BMP 
signalling and the subsequent migration of cells through the primitive streak has been 
shown to be controlled by FGF and WNT signalling (43-47).  Manipulation of all these 
molecular pathways using cytokines and small molecule agonists and antagonists during the 
differentiation of PSCs in vitro has resulted in the design of differentiation protocols to 
favour mesoderm rather than endoderm and ectoderm production and to control anterior-
posterior patterning (48-53).   The fate of nascent primitive streak cells are marked by 
expression of the transcription factors Mxl1, Brachyury/T and GSC and their fate to anterior 
endoderm or posterior mesoderm progenitors in differentiating hPSC can be modulated by 
manipulation of the Activin/Nodal and BMP signaling pathways (51).  Initial studies to 
enhance the production of mesoderm from differentiating hPSCs relied on the 
quantification of these mesodermal-related proteins or RNA transcripts in dissociated cells 
(41, 53). However, the production of reporter hPSC lines to track the cell lineages of interest 
in real time allowed more efficient and high-throughput strategies for protocol testing. For 
example, the generation of the Mixl1-GFP reporter hESC line provided an important 
resource to explore germ layer specification of differentiation in hPSC and to show that 
many of the mesoderm inducing processes, first identified in the mouse embryo, are 
conserved in human (54). Importantly, the use of this reporter hESC line confirmed the 
importance of BMP4 signalling in mesoderm differentiation in hESC differentiation (54). 
Profiling of Mixl1-GFP expressing cells identified additional mesodermal markers including 
APLNR as cell surface marker for this stage of differentiation (55-57). Mesoderm that 
differentiates from hPSCs in the presence of BMP4 were considered to be comparable to 
cells of the posterior primitive streak and express APLNR, KDR (FLK1) and PDGFRa.  These 
cells lack of expression of endothelial (CD31), haematopoietic (eg CD43 or CD45) or 
endothelial/mesenchymal (CD73, CD105) markers (33) but in the presence of FGF2 and 
VEGF they differentiate into progenitors with both endothelial and haematopoietic 
potential that can be tracked by their expression of KDR and their potential to generate 
blast colonies (BL-CFC) (Figure 1) (58, 59).  Signalling pathways involved in the modulation of 
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mesoderm generation and specification also impact on the balance between the production 
of cells that resemble extra-embryonic haematopoietic cells (eg primitive erythroid cells and 
erythromyeloid progenitors (EMPs)) and definitive-like haematopoietic progenitors that 
arise in the AGM of the embryo (34, 52, 60).  For example, the  production of primitive 
haematopoietic cells, marked by expression of CD235a, is temporally dependent on the 
activin-nodal pathway whereas the production of definitive -like progenitors that express 
Runx1 is not (52). Simultaneous activation of WNT and inhibition of the TGFb pathway 
favours the production of definitive AGM-like haematopoietic progenitors that are also 
marked by the upregulation of HOXA gene expression (34). 
 
3.2. Endothelial to haematopoietic transition. 
 
Haematopoietic cells arise from specialised haemogenic endothelial cells (HECs) at the 
various haematopoietic sites during embryonic development in a process known as 
endothelial to haematopoietic transition (EHT) (24, 26). HECs express the endothelial 
surface markers VE-cadherin, CD31 and KIT and the transcription factors RUNX1 and GATA2 
(16).  The process of EHT has been described in differentiating mouse and human PSCs (16, 
60, 61). During hPSC differentiation, endothelial cells can be identified using typical 
endothelial markers such as VE-cadherin (CD144), CD31 and CD34 and the absence of the 
pan-hematopoietic marker CD43 (33). Although CD34 is commonly used to enrich for adult 
HSCs from umbilical cord blood or mobilised peripheral blood, it is not specific for HSPCs in 
differentiating hPSC as it is also expressed on endothelial cells and mesenchymal cells. The 
finding that the marker CD43 could be used to separate haematopoietic cells from these cell 
populations represented a significant advance in the field (62).  
 
The heterogeneity of hPSC-derived endothelial cells and the lineage relationship between 
haemogenic endothelium and haematopoietic progenitors was addressed using a Runx1c-
tdTomato reporter hESC line in one of the first single cell transcriptional analyses of 
differentiating hPSCs (63). The study demonstrated that haematopoietic potential was 
restricted to the Runx1C-tdTomato+ endothelial cells (CD31+CD144+). RNA sequencing 
confirmed SOX17 as marker for HE as previously described (60, 64), and identified novel 
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markers, including TIMP3, ESAM, RHOJ,  and DLL4,  that distinguished haemogenic 
endothelium from the Runx1C- endothelium (63). 
 
A more extensive single cell transcriptional analyses of index sorted hPSC-derived cells was 
carried out to further characterise the EHT process (65). Transcriptional profiling of almost 
500 CD34+ cells revealed the heterogeneity of endothelial cells and the presence of 
transitionary cells that expressed both endothelial and haematopoietic genes. This analysis 
revealed a continuum of endothelial and haematopoietic signatures with increasing 
expression of GFI1b correlating with a loss of endothelial gene expression and the 
subsequent upregulation of other haematopoietic transcription factors such as 
TAL1, LYL1, GATA2 and RUNX1. One of the most interesting and somewhat surprising 
findings from this study was that the endothelial-haematopoietic transitionary population 
consisted of sub-populations that expressed markers of specific haematopoietic lineage 
commitment, implying that haematopoietic lineage restriction occurs prior to completion of 
the EHT process (65).   
 
The emergence of endothelial and haematopoietic lineages in differentiating hESCs was 
characterised in more detail using a double reporter cell line where mCherry marked the 
expression of SOX17 in endothelium and GFP marked the RUNX1C isoform in 
haematopoietic progenitors (34, 60). In these studies, specific culture conditions were 
employed to mimic either extraembryonic yolk-sac like and intraembryonic AGM-like 
haematopoiesis. Transcriptional profiling was performed on cells progressing through the 
different stages of yolk-sac-like haematopoiesis including PDFGRa+ mesoderm, 
CD34+SOX17- and CD34+SOX17+ endothelial cells and the emerging CD34+CD43+ 
haematopoietic cells.  Findings from this analysis supported the concept that SOX17- 
endothelial cells differentiate into either a haematopoietic or an endothelial cell fate 
consistent with the presence of an haemangioblast intermediate whereas acquisition of 
SOX17 expression was associated with the generation of non-haemogenic endothelial cells 
(60). 
 
The above single cell transcriptomic studies provided valuable insight into the production of 
hPSC-derived HSPCs but they depended on the use of known markers for their 
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identification. Specifically, CD34 and CD43 have been used to define the hPSC-derived 
HSPCs but, although it is known that CD43 marks the majority of hPSC-derived HSPCS, it is 
not clear whether this marker is expressed on all HSPCs and specifically on the most potent 
HSCs capable of long-term reconstitution. Single cell RNA sequencing studies and lineage 
tracing of haematopoietic cell populations in vivo have revealed that HSPCs are far more 
heterogeneous than first thought, impacting on our characterisation of in vitro-generated 
HSPCs (66)  Some cells within the phenotypic HSC compartment expressed transcriptional 
programs associated with lineage committed progenitors. For example, genes associated 
with the megakaryocyte lineages including von Willebrand factor, are expressed in a subset 
of HSCs (67).  There is now strong evidence  for the existence of lineage-biased HSCs 
conflicting with the traditional view of the haematopoietic hierarchy (reviewed in (66)).   
 
4. Characterisation of hPSC-derived HSPCs. 
To define the heterogeneity of hPSC-derived HSPCs and to assess their lineage trajectory, 
we designed a minimal membrane marker strategy that allows an unbiased isolation of 
hPSC-derived HSPCs that were then subjected to single cell RNA-Seq and CITE-Seq 
(Cellular Indexing of Transcriptomes and Epitopes by Sequencing) analyses (68). CITE-Seq 
strategy adds an additional dimension because it incorporates quantitative information on 
cell surface marker expression at the protein level. Antibodies against cell surface markers 
of interest are labelled with oligonucleotides from which antibody-derived tags (ADTs)can 
be obtained and identify the cells that express that marker in subsequent single cell RNA 
sequence analyses. It provides a really powerful approach particularly in the haematopoietic 
system where so many markers are known and it offers the ideal strategy to define the 
transcriptome of cells expressing novel markers without the need for cell sorting. We used 
this approach to confirm the expression of a number of novel markers in naïve and lineage 
committed progenitors that we had identified by clustering and trajectory analyses. For 
example, we identified and confirmed CD44 as a marker for naïve progenitors which has 
been since reported by others in single cell sequencing experiment (69) and as a endothelial 
cell marker in mouse AGM (70). We also identified CD326 (EPCAM) as a marker of 
haematopoietic progenitors committed to the erythroid lineage and confirmed this finding 
in erythroid progenitors differentiated from human haematopoietic progenitors derived 
from umbilical cord blood. ICAM2 and CD9 were identified as markers associated with 
 10 
megakaryocyte-committed progenitors. Myeloid-committed cells were marked by 
expression of CD18 but sub-clustering of the transcriptional dataset revealed that this CD18+ 
population could be subdivided into progenitors with eosinophil, neutrophil, and monocyte 
potential (71). 
 
In addition to the expected markers such as CD34, CD44 and CD33 we also identified CD132, 
CD52, CD180 and IL3RA as potential candidate markers for the most potent HSC-like cells 
and propose these could be used both for their isolation and track their production. Gene 
network analyses identified LMO4 as a potential regulatory transcription factor that had not 
been previously associated with HSPCs.  Interestingly we also identified  ID2 and ID4 in naïve 
progenitors that, as targets of BMP signalling, could provide one of the mechanisms 
associated with the important role of this pathway in HSPC production (71).  
 
5. The haematopoietic hierarchy. 
 
Although it has provided an excellent framework for experimental haematology, there is 
increasing evidence against the classical hierarchical model of haematopoiesis where 
mature cells of the blood are generated via multipotent, oligopotent then unipotent 
progenitor cells (72-74). The use of additional markers to subset common myeloid 
progenitors (CMP) and improved assays for function readouts (73) as well as impressive 
single cell transplantation assays (72) have demonstrated that myeloid cells can be 
generated directly from HSC without progressing through an intermediate CMP. There is 
also strong evidence for the existence of HSCs that are biased towards the production of 
platelets that could be activated in acute emergency situations such as life-threatening 
platelet depletions associated with acute inflammation (75).  Single cell transcription 
analyses support the idea of a continuum of differentiation states rather than discrete cell 
stages (74, 76-78).   
 
Trajectory analyses of hPSC-derived HSPCs also demonstrated a continuum of cell states to 
specific cell lineages as opposed to a sequential  hierarchy of discrete cell types (71).  We 
identified a central cluster of naïve progenitors that expressed known markers of 
multipotent HSPCs, such as GATA2, and a number of trajectory branches comprising 
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continua of cells each expressing genes associated with specific lineages. An erythroid 
branch marked by the expression of KLF1 and MYC, as well as a megakaryocyte branch by 
expression of GATA1, TAL1 and FLI1 were identified.  Granulocyte-committed cells were 
represented by a separate branch and demonstrated the expression of CEBPD, CEBP-B, 
CEBP-A and CEBP-E. 
 
6. Comparison of in vitro and in vivo-derived HSPCs. 
 
CD43 has been widely used as a marker for hPSC-derived HSPCs but we noted that, although 
the majority of suspension cells arising from the adherent endothelium expressed this 
marker, there was a small proportion of RUNX1C-GFP+  cells that were CD43-negative (71).  
Intrigued by this finding, we carried out one single cell RNA sequencing experiments on 
CD43+ selected cells and another that captured both CD43+ and CD43- cells. We then 
compared the transcriptional profile of these populations with in vivo-generated cells using 
machine learning. We first trained an artificial neural network (ANN) on a scRNA-seq dataset 
derived from human fetal liver (78) then used that to ‘recognise’ the comparable cell types 
that were generated in vitro from hPSCs. A range of HSPC phenotypes were identified 
including a rare population that could be classified as HSCs. This HSC-like population was 
transient, present in the suspension cells at day 10 but decreased in number when cells 
were collected later at day 13. Most interestingly, this population was completely absent 
from the dataset that had been generated using cells selected on the basis of CD43 
expression (71). This implies that the most immature human HSCs might not express CD43, 
a phenotype that is comparable to mouse Pro-HSCs prior to their maturation into functional 
definitive HSCs (79), and that the culture conditions employed are not conducive to their 
maintenance and/or maturation.     
 
By comparing the single cell transcriptome of in vitro-generated HSC-like cells with those 
colonising the foetal liver (78), we identified transcription factors and molecular pathways 
that can be targeted in the aim of improving HSC differentiation in vitro. For example, EGR1 
and other members of the early response genes family (ZFP36L1, NR4A1, FOS, JUN, and 
JUNB) were expressed at a lower level in the in vitro–produced HSC-like cells, and we 
propose these could be useful in direct programming strategies for HSC production. 
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It is important to note that some of the transcriptional differences between in vivo and in 
vitro derived HSPCs possibly reflect in vitro culture conditions rather than intrinsic 
differences. For example, we detected differences in the expression of genes associated 
with oxidative phosphorylation indicating metabolically differences (71)  which is not 
surprising considering that oxygen levels in normoxic culture are likely to be significantly 
higher than in the reported hypoxic environment in the AGM and foetal liver (71, 80). We 
also reported higher expression of genes associated with the cell cycle in the in vitro HSPCs 
compared to those of the foetal liver. The quiescent nature of the most potent HSCs is well 
documented with exit from the quiescent state being a critical step in the production of 
HSCs (81, 82). Given the cocktail of cytokines required for the complex in vitro PSC 
differentiation it is unlikely that that quiescent state is replicated in these conditions.  
However, the recent characterisation of HSC in hibernation conditions at the single cell level 
will hopefully provide insight into this critical step during HSC production (65).  
 
7. Summary 
The production of fully function therapeutic haematopoietic cell types from hPSCs has 
enormous potential for the future treatment of disease but success in their production in 
vitro is dependent on our ability to recapitulate the paths involved in their development and 
maintenance in vivo. Here we review the key steps and transitional events in embryonic 
haematopoiesis that have been considered in the design of differentiation strategies as well 
as the marker strategies used to monitor the production of HSPCs from hPSCs.  The design 
and implementation of improved protocols is expected to follow from the transcriptional 
comparison of in vitro and in vivo generated cells (71).  It is evident that the use of precisely 
defined culture conditions have some limitations and so future strategies may well return to 
the use of stromal cells and organoids in 3D perfusion bioreactors to mimic the complex 
conditions required for the production and maintenance of HSCs (83). It is now well 
established that hemodynamic forces are required for HSPC formation in vivo and so the 
application of sheer stress to differentiating hPSCs or the activation of genetic pathways 
that are activated by mechanical forces may provide one of the vital steps in the production 
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10. Figure Legends 
 
Table 1 
Characteristics of human PSC-derived haematopoietic cells compared to their counterparts 
generated in vivo. 
 
Figure 1 
Differentiation of human pluripotent stem cells into haematopoietic cells highlighting the 
signalling pathways that have been modulated to control the key transitionary steps and the 
molecular markers that have been used to track the process. 
